Effekte von Cisplatin und Carboplatin auf verschiedene Biomarker im Urin

Effects of Cisplatin and Carboplatin on different urinary biomarkers

by Kathi Goldstein
Doctoral thesis
Date of Examination:2016-08-08
Date of issue:2016-07-28
Advisor:Prof. Dr. Sabine Blaschke
Referee:PD Dr. Abdul Rahman Asif
Referee:Prof. Dr. Rainer Mausberg
Persistent Address: http://dx.doi.org/10.53846/goediss-5763

 

 

Files in this item

Name:SUB_eDiss-Version (ohne Lebnslauf)pdf.pdf
Size:1.92Mb
Format:PDF

The following license files are associated with this item:

Abstract

English

Cis- and Carboplatin are frequently part of a cytostatic therapy and have potential nephrotoxic side effects. Early detection of renal damage is of outmost clinical relevance to prevent acute renal failure. However, the standard clinical tests for detection of kidney injury - especially serum creatinine measurements - are insensitive and detect only advanced stages of injury. Therefore, a variety of urinary biomarkers is currently under evaluation to identify biomarkers for early detection of kidney injury. Most studies analyze only changes in one or a few biomarkers, thus information on a direct comparison of a larger number of different markers is limited. This study compares changes a variety of different renal biomarkers measured by clinical chemistry and Luminex-based technology. Markers of the proximal tubule (ßNAG, α1MG, ß2MG) reacted fastest to therapy with platin-derivates and may be eligible for early detection of renal damage. Increased levels of proximal (α1M, Kim-1) and glomerular (osteopontin) markers in the urine.of patients with diabetes may reflect a higher susceptibility to kidney damage. Further studies in larger cohorts have to evaluate clinical sensitivity and specificity of these urinary biomarkers.
Keywords: Cisplatin; Carboplatin; Kidney injury; biomarkers; cytostatic therapy
Schlagwörter: Cisplatin; Carboplatin; Biomarker; Nierenversagen
 
Statistik